ALQ +1.95%: technical testing company ALS presented FY22 numbers to the market today, coming in slightly ahead of expectations. Revenue grew 24% to $2.2b, and EBIT was up 36% for the year to $409m, around 2% ahead of consensus. The commodities segment saw EBIT growth of over 40% thanks to a strong tailwind of volumes and price increases. Life Sciences also saw solid growth, organic EBIT growth of 29% plus an additional $11m contribution from recently acquired businesses. The report brings to an end a 5 year strategic plan with each of the targets met or exceeded. They didn’t provide any FY23 guidance but did say the business has continued to perform solidly since the end of the period, with more to come at the AGM in August.
scroll
Performance update for March, stocks that drove returns & our current positioning
Close
Tuesday 23rd April – ASX200 +26pts, Northern Star (NST), Chrysos (C79), Brambles (BXB)
Close
Market Matters Research Lead Shawn Hickman with David Koch
Close
Tuesday 23rd April – DOW up +253pts, SPI up +19pts
Close
MM is mildly bullish ALQ
Add To Hit List
Relevant suggested news and content from the site
Video
WATCH
Performance update for March, stocks that drove returns & our current positioning
Recorded Tuesday 9th April
Podcast
LISTEN
Tuesday 23rd April – ASX200 +26pts, Northern Star (NST), Chrysos (C79), Brambles (BXB)
Daily Podcast Direct from the Desk
Video
WATCH
Market Matters Research Lead Shawn Hickman with David Koch
Recorded Monday 25th March
Podcast
LISTEN
Tuesday 23rd April – DOW up +253pts, SPI up +19pts
Daily Podcast Direct from the Desk
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.